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INTRODUCTION
Chloroquine resistant malaria remains a major cause
of morbidity and mortality in sub Saharan African
children . Although the World Health Organisation
(WHO) has recommended Artemisin-based
Combination therapies (ACTs) as the best anti-
malarial drugs currently available , the use of ACTs
in clinical practice has remained very low due to
several limitations including high cost, low public
awareness, limited data on safety particularly during
pregnancy and insufficient supply relative to
demand . Given these limitations, the diffusion of
the WHO ACT guidelines into routine clinical
practice is likely to take many years particularly in
poor developing countries where chloroquine
remains an important drug in malaria chemotherapy,
despite the widespread resistance of
to chloroquine .Given the relatively low
cost and ready availability of chloroquine, evaluation
of drug combinations that reverse the resistance of










in order to prolong its “clinical life” for susceptible
populations with limited or no access to ACTs. The
resistance of to chloroquine can be
modified and reversed by non-antimalarial
drugs including antihistamines (promethazine and
chlorpheniramine), calcium channel antagonists
(verapamil) and phenothiazines . In-vivo studies also
demonstrate the efficacy of chlorpheniramine in
reversing chloroquine resistance and preliminary data
suggests that this reversal may be dose dependent,
with increasing efficacy for reversal demonstrated
with higher doses of chlorpheniramine combined
with high dose chloroquine therapy . However, data
is sparse on the clinical adverse effects associated with
higher dose chlorpheniramine-chloroquine (CP+CQ)
combination therapies, particularly in the pediatric age
group. In this study, we examined the adverse clinical
effects of high dose chlorpheniramine (6-8 mg stat,
then 12-18 mg/day X 7days) versus higher dose
chlorpheniramine (9-12 mg stat, then 18-24 mg/day X
7days) in combination with high dose chloroquine
(30mg/kg body weight) in a pediatric population in
western Africa. The usual therapeutic dose of
chloroquine is 25mg/kg body weight and the usual
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To compare the adverse effects of two regimens of chlorpheniramine plus chloroquine (CP+CQ) in
children who live in a country where chloroquine resistant malaria is endemic.
99 children with acute uncomplicated malaria were randomised into two treatment groups. Group I
received high dose chlorpheniramine (6mg +12mg/day for 7days in children = 5years; 8mg + 18mg/day for 7
days in those >5years) plus chloroquine 10mg/kg daily for 3 days. Group II received a 50% higher dose of
chlorpheniramine plus chloroquine 10mg/kg daily for 3 days. Outcome measures were vital signs, clinical
response and parasite clearance on days 0-7 and day 14.
Parasite clearance, fever clearance and cure rate were comparable for the two groups. Drowsiness
occurred in 66.7% of high dose and 86.3% of higher dose CP+CQ subjects (p = 0.05). Compared to children
treated with high dose, those treated with higher dose CP+CQ had significantly lower respiratory rates on day 2
(p = 0.001), day 6 (p = 0.015), and on day 14 (p = 0.003).
The higher rates of drowsiness and lower respiratory rates in children treated with higher dose
CP+CQ calls for caution in the clinical application of the higher dose combination. The higher dose has no
additional benefit and may in fact be dangerous.
Chloroquine resistant malaria, chlorpheniramine-chloroquine, treatment, adverse effects,
drowsiness, respiratory depression.
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12mg/day for 3 days. The higher doses of
chlorpheniramine used in this study reflect the
chloroquine resistance modifying effect of the
chlopheniramine, rather than the lower
antihistaminic doses of chlorpeniramine, used to
treat pruritus associated with chloroquine therapy.
We present data on the prevalence of adverse effects
of high dose chlorpheniramine combination
therapies used to modify chloroquine resistance in
Nigerian children diagnosed with acute
uncomplicated falciparum malaria.
The study subjects were selected from pediatric
patients attending the General Out Patient Clinic,
University College Hospital, Ibadan, Nigeria. The
study protocol was approved by the Joint University
of Ibadan/University College Hospital Institutional
Review Committee. Informed consent was obtained
from parents or legal guardians of the children
selected for the study.A total of 106 consecutive
children aged 9 months to 14 years presenting with
acute uncomplicated malaria that
satisfied the inclusion criteria were enrolled into the
study. The inclusion criteria were as follows: fever
or history of fever in the 24-48 hours before
presentation, clinical symptoms compatible with
acute uncomplicated falciparum malaria, pure
parasitaemia with parasite
density >1000 asexual forms/µl of blood, and
absence of concomitant illness such as
bronchopneumonia. A detailed medical history was
obtained and a standardized physical examination
was performed for each subject. Vital signs
including pulse rate, respiratory rate, systolic and
diastolic blood pressure, were performed. Body
weight, height and axillary temperature were also
recorded by the same observer. The clinical data
were collected with a study-specific Case Record
Form. Thick and Thin blood films from finger
pricked capillary blood were obtained and Giemsa
stained for identification and quantification of
malaria parasites. Subjects were randomized to
receive one of two treatment regimens, using pre-
packed sealed envelopes. Each envelope was
opened only after the subject had been recruited into
the study. The treatment assignments were as
follows: Group I (High dose Chlorpherinamine +
Chloroquine): Subjects received chloroquine (30 mg
base/kg of body weight) orally as 10 mg/kg daily
over 3 days plus chlorpheniramine mealate 6mg
orally start dose at presentation, followed by
12mg/day orally in three divided doses every 8 hours
for 7 days (days 0-6) if they were 5 years and below.
For subjects who were older than 5 years, they
received a start dose of 8 mg of chlorpheniramine
followed by 18mg/day orally in three divided doses




chloroquine (10 mg/kg daily over 3 days) as described
above. Group II (Higher dose Chlorpheniramine +
Chloroquine): Patients in this group received
chloroquine (30mg base/kg of body weight) orally as
10mg/kg daily over 3 days plus chlorpheniramine 9 mg
orally start dose at presentation, followed by 18mg/day
orally in three divided doses every 8 hours for 7 days
(days 0-6) if they were 5 years and below . For
subjects who were older than 5 years, they received a
start dose of 12 mg of chlorpheniramine followed by
24mg/day orally in three divided doses every 8 hours
for 7 days (days 0-6) in addition to chloroquine (10
mg/kg daily over 3 days) as described above.The
chloroquine doses and first daily doses of
chlorpheniramine were administered by the study
physician and subjects were observed in the clinical
unit for at least 3 hours each day. The subsequent daily
doses of chlorpheniramine were administered at home
by the parents/guardian. Clinical observations were
recorded daily from days 0-7 and on day 14 by a single
observer who was blinded to the treatment
assignments. Vital signs including temperature, pulse
rate, blood pressure and respiratory rate, and an
assessment of drowsiness/sedation were checked daily
at each clinic visit before thick blood films for parasite
quantification were performed. The parent/guardian
gave information on the drug administration (at home)
and adverse effects including drowsiness/sedation,
pruritus, and nausea and/or vomiting, abdominal pain
and diarrhea at each clinical visit.The fever and
parasite clearance times, and cure rates were also
determined. Fever clearance time was defined as time
from drug administration until the axillary temperature
was below 37.5 C and remained so for at least 72 hours.
This definition was necessary because of the routine
use of an antipyretic (paracetamol) during the first 36
hours of treatment. The parasite clearance time was
defined as the time from drug administration until there
was no patent peripheral parasitaemia. The cure rate
was defined as the proportion of children who
remained free of parasitaemia on day 14 of follow-up .
Data were analyzed using . Data is
presented as mean and standard deviation for normally
distributed values and are compared using student's t-
test. Chi-square with Yate's correction or by Fisher's
exact test is used for comparing proportions. Mann-
Whitney U test is used to compare skewed data which
are presented as median and interquartile range.
Differences are deemed to be statistically significant
where p< 0.05.
Of the 106 subjects enrolled into the study, 99 subjects
(93.4%) completed the study. One subject developed
severe complicated malaria on Day 0, and as such
could not continue in the study while 6 subjects were
0
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Data and statistical Analysis
RESULTS
Epi-Info version 6
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Table 1
*Fisher's exact test
Respiratory rate showed a skewed distribution, the
median and interquartile range was reported.High
dose CP+CQ: Chlorpheniramine 6-8 mg stat, then 12-
18 mg/day X 7days + Chloroquine 10mg base/kg X
3days
Higher dose CP+CQ: Chlorpheniramine 8-12 mg stat,
then 18-24 mg/day X 7days + Chloroquine 10mg
base/kg X 3days
Table 2:
Clinical and Parasitology Parameters of
Children with Acute Malaria at
Baseline.
Adverse effects of two treatment regimens
of chlorpheniramine plus chloroquine (CP+CQ) in




High dose CP+CQ: Chlorpheniramine 6-8 mg stat, then 12-18
mg/day X 7days + Chloroquine 10mg base/kg X 3days
Higher dose CP+CQ: Chlorpheniramine 8-12 mg stat, then 18-
24 mg/day X 7days + Chloroquine 10mg base/kg X 3days
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lost to follow up. Forty-eight subjects were in Group
I (high dose chlorpheniramine + chloroquine), while
51 were in Group II (higher dose chlorpheniramine +
chloroquine).
Table 1 shows the
clinical and parasitological characteristics of
subjects in the two treatment groups at baseline.
There was a higher proportion of females in Group I
compared to Group II (68.8% versus 52.9%)
although the difference did not achieve statistical
significance (p =0.215). The age, weight and vital
signs were comparable in the two treatment groups.
The mean parasite density was similar
in the two groups although two subjects in Group I
had parasitaemia in excess of 250,000/ul (See Table
I).
: The mean parasite
clearance time was similar in both treatment groups.
For Group I (high dose CP+CQ) it was 2.8 0.7 days
(range 1-5 days) and for Group II (higher dose
CP+CQ), it was 2.9 0.7 days (range 2-4 days)
(p=0.58) (Figure 1). Mean fever clearance time was
1.40.7 days (1-3days) and 1.30.7 days (1-4days) for
Group I and II respectively (p=0.68) The
cure rates on day 14 was 95.8% for Group I and
94.1% for Group II (p=0.94).
Drowsiness/sedation was
the most common reported adverse effect of
treatment, occurring in 66.7% of Group I (high dose
CP+CQ) and 86.3% of Group II (higher dose
CP+CQ) subjects (p = 0.05). Pruritus was slightly
more common in the higher dose treatment group
relative to the high dose group (29.4% versus 22.9%)
although it did not achieve statistical significance.
Reports of diarrhea, abdominal pain, and, nausea and
vomiting were comparable in the two treatment
groups (Table 2).Vital signs obtained on clinic visits
from days 0-7 and on day 14 showed that the mean
pulse rate was similar in both treatment groups
(Table 3). However, more patients in Group II had a
pulse rate of more than 100/min on days 7 (64%) and
14 (62%) compared to those in Group I, 54% and
59% respectively. Mean systolic and diastolic blood
pressure in the two treatment groups were largely
comparable, although on day 3, mean systolic blood
pressure was slightly higher in Group II relative to
Group I (111 mmHg versus 107 mmHg, p = 0.05)
See Table 4. The respiratory rate distribution was
skewed; hence the median respiratory rate is
reported. Table 5 shows that relative to Group I,
Group II (higher dose CP+CQ) subjects tended to
have lower respiratory rates in response to treatment
with statistically significant differences on day 2 (p =
0.001), day 6 (p = 0.015), and on day 14 (p = 0.003).














*Female (%) 68.8 52.9 0.215




































































Group I (High Dose
CP+CQ) N = 48
Group II (Higher
Dose CP+CQ) N = 51
P value
Drowsiness 32 (66.7%) 44 (86.3%) 0.05
Pruritus 11 (22.9%) 15 (29.4%) 0.64
Diarrhea 5 (10.4%) 6 (11.8%) 1.0
Abdominal pain 4 (8.3%) 4 (7.8%) 1.0
Nausea and
vomiting
3 (6.3%) 3 (5.9%) 0.71
Table 3:
High dose CP+CQ: Chlorpheniramine 6-8 mg stat,
then 12-18 mg/day X 7days + Chloroquine 10mg
base/kg X 3days
Higher dose CP+CQ: Chlorpheniramine 8-12 mg stat,
then 18-24 mg/day X 7days + Chloroquine 10mg
base/kg X 3days.
Table 4:
*All blood pressure measurements were taken in the
supine position; mmHg millimeters of mercury.
High dose CP+CQ: Chlorpheniramine 6-8 mg stat,
then 12-18 mg/day X 7days + Chloroquine 10mg
base/kg X 3days
Higher dose CP+CQ: Chlorpheniramine 8-12 mg stat,
then 18-24 mg/day X 7days + Chloroquine 10mg
base/kg X 3days
Pulse Rate in Children with Acute
Malaria Treated With Two Regimens of
Chlorpheniramine Plus Chloroquine (CP+CQ).
Systolic and Diastolic Blood Pressure in
Children withAcute Malaria Treated






*Clinical observations on days 0-7 and on day 14.
High dose CP+CQ: Chlorpheniramine 6-8 mg stat,
then 12-18 mg/day X 7days + Chloroquine 10mg
base/kg X 3days
Higher dose CP+CQ: Chlorpheniramine 8-12 mg
stat, then 18-24 mg/day X 7days + Chloroquine 10mg
base/kg X 3days.
Figure 2:
*Clinical observations on days 0-7 and on day 14.
High dose CP+CQ: Chlorpheniramine 6-8 mg stat,
then 12-18 mg/day X 7days + Chloroquine 10mg
base/kg X 3days
Higher dose CP+CQ: Chlorpheniramine 8-12 mg
stat, then 18-24 mg/day X 7days + Chloroquine 10mg
base/kg X 3days
Rate of Fever Clearance in Children with
Acute Malaria Treated With Two
Regimens of Chlorpheniramine Plus Chloroquine
(CP+CQ)
Rate of Parasite Clearance in Children
with Acute Malaria Treated With





























Group I (High dose CP+CQ)
Group II (Higher dose CP+CQ)









Day 0 76-180 120 24 76-172 121 22 0.87
Day 1 76-144 107 17 84-176 114 20 0.07
Day 2 72-152 105 19 68-168 108 22 0.51
Day 3 72-148 101 16 76-140 102 15 0.77
Day 4 76-136 100 15 68-152 102 17 0.56
Day 5 72-112 93 17 68-112 92 17 0.78
Day 6 68-144 91 26 72-124 101 18 0.19
Day 7 68-140 103 16 68-140 104 15 0.75
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Table 5:
Mann-Whitney U test
High dose CP+CQ: Chlorpheniramine 6-8 mg stat,
then 12-18 mg/day X 7days + Chloroquine 10mg
base/kg X 3days
Higher dose CP+CQ: Chlorpheniramine 8-12 mg
stat, then 18-24 mg/day X 7days + Chloroquine
10mg base/kg X 3days.
Respiratory Rate in Children with Acute
Malaria Treated With Two





In this study, we compared the clinical adverse
e f f e c t s o f tw o d o s e c o m b in a t i o n s o f
chlorpheniramine and chloroquine. The indices of
therapeutic responses, parasite and fever clearance
times in children enrolled in the study were similar in
both treatment groups. This suggests that the higher
dose CP+CQ had no therapeutic advantage over high
dose CP+CQ in malaria cure rates in our study
population. However, the persistent tachycardia on
days 7 and 14 and slightly elevated systolic blood
pressure on day 3 which is more with the higher dose
group may suggest cardiac toxicity of the
combination or of chlorpheniramine alone. There is
also the possibility of other febrile illnesses which
may be setting in at this time. The most important
finding in this study was significantly lower
respiratory rates in the higher dose CP+CQ group
relative to the high dose group. The lower respiratory
rates were present on several days of treatment and
extended beyond treatment, persisting even on day
14 (p=0.003). Abnormalities in respiratory rate and
pattern are common clinical manifestations of
malaria and/or acute respiratory tract infection, both
of which are major causes of childhood morbidity and
mortality in sub Saharan Africa. Appropriate
management depends on accurate assessment which
for most children is based on clinical signs alone.
Abnormal respiratory pattern has been reported in
severe malaria and is often associated with poor
prognosis Hypoventilation in malaria has been
suggested to be either drug-related particularly when
diazepam is administered prior to anti-malarial therapy
or due to subtle seizure activities . None of the
subjects in this study had complicated malaria. In
addition, the lower respiratory rate observed during the
course of treatment in the higher dose CP+CQ group
was not present at presentation but was observed on
day 2 after the initiation of CP + CQ combination
therapy. Therefore, the lower respiratory rates in
Group II subjects may be attributable to the higher dose
of chlopheniramine (9-12 mg stat, then 18-24 mg/day
X 7days) used in this study. The most common reported
clinical adverse event in this study was
drowsiness/sedation. This occurred more frequently in
the higher dose CP+CQ group relative to the high dose
group (86.3% vs. 66.7%; p = 0.05). While this may be
an advantage in agitated patients, it may mask
symptoms of central nervous system deterioration
including mild seizure episodes in complicated
malaria. The parasitaemia counts of over one million
per microlitre of blood seen in this study are not
uncommon in endemic areas and may not necessarily
indicate severity of infection . Pruritus was common
in the two treatment groups and its occurrence was
slightly higher in the higher dose CP+CQ group
relative to the high dose CP+CQ group (29.4% vs.
22.9%; p=0.64). This finding suggests a lack of
efficacy of higher doses of anti-histamines in the
treatment of chloroquine-induced pruritus. The
reversal of drug resistance in P.falciparum malaria
using chloroquine combinations with medications
such as antihistamines , calcium channel antagonists
and phenothiazines may have potential toxic effects on
the host cells. For example, the combination of high
doses of chloroquine and verapamil has been reported
to result in the death of well differentiated normal
human cells, although the cells survived the same
concentration of either drug alone . The lower
respiratory rates and higher rates of sedation in
children treated with higher dose CP+CQ in this study
calls for caution in the administration of high dose drug
combinations for malaria therapy in children. In the
vast majority of sub Saharan Africa hospitals where
state-of-the-art diagnostic facilities are extremely
limited, clinical signs may provide the only indication
of adverse effects of drug therapy. This underscores the
need for clinical assessment and close observation of





















Day 0 32 36 0.88
Day 1 32 28 0.28
Day 2 32 28 0.001
Day 3 32 28 0.09
Day 4 28 28 0.34
Day 5 32 28 0.27
Day 6 31 25 0.015
Day 7 28 28 0.09
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